TerminatedNot Applicable

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

Stopped: We were informed by the NCI that this research no longer aligns with NCI values, therefore our grant was terminated and we had received a stop work order.

United States29 participantsStarted 2024-11-13

Plain-language summary

The objective of this study is to assess the use of and satisfaction with the ECA-HPV intervention over a 16-month period, its ability to increase HPV vaccination, and the comparative effectiveness of clinic notification and adolescent ECA components on these factors.

Who can participate

Age range8 Years – 12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Speaks English fluently
✓. Able to independently consent
✓. Has adequate corrected vision to use the ECA-HPV system (based on their ability to go through the consent form)
✓. Has adequate hearing to use the ECA-HPV system (based on their ability to hear the research staff member conducting the consent process)
✓. Has a smartphone that is able to support the ECA-HPV app
✓. Is between the ages of 9-12 at the time of the index (first) well child visit
✓. Has received either 1 or none of the HPV vaccine series
✓. Speaks English fluently

Exclusion criteria

✕. Is not able to use the ECA-HPV system
✕. Has already participated in the study before

What they're measuring

HPV vaccination series completion comparing the control group to the intervention groups

Timeframe: 16 months

HPV vaccination series completion comparing the intervention groups

Timeframe: 16 months

Trial details

NCT IDNCT06367699

SponsorTufts Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-04-01

View on ClinicalTrials.gov More Human Papilloma Virus trials